<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected studies of systemic therapy for brain metastases from breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected studies of systemic therapy for brain metastases from breast cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected studies of systemic therapy for brain metastases from breast cancer</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Study </td> <td class="subtitle1">Regimen </td> <td class="subtitle1">Patient population </td> <td class="subtitle1">Total number of patients </td> <td class="subtitle1">Number of patients with breast cancer and brain metastases </td> <td class="subtitle1">Objective response rate (percent) </td> <td class="subtitle1">TTP/PFS </td> <td class="subtitle1">Comments </td> </tr> <tr> <td>Rosner et al<sup>[1]</sup></td> <td>Various (CFP, CFPMV, MVP, CA)</td> <td>Breast cancer</td> <td>100</td> <td>100</td> <td>50</td> <td>NR</td> <td>Case series</td> </tr> <tr> <td>Boogerd et al<sup>[2]</sup></td> <td>Oral CMF (n=20), or CAF (n=2)</td> <td>Breast cancer</td> <td>22</td> <td>22</td> <td>54</td> <td>NR</td> <td>Case series</td> </tr> <tr> <td>Friedman et al<sup>[3]</sup></td> <td>Temozolomide 150 mg/m<sup>2</sup> days 1-7, 15-21, every 28 days</td> <td>Solid tumors</td> <td>52</td> <td>15</td> <td>6</td> <td>NR</td> <td>No responses seen in breast cancer patients</td> </tr> <tr> <td>Siena et al<sup>[4]</sup></td> <td>Temozolomide 150 mg/m<sup>2</sup> days 1-7, 15-21, every 28 days</td> <td>Solid tumors</td> <td>62</td> <td>21</td> <td>19 (in subset of patients with breast cancer)</td> <td>1.9 months</td> <td> </td> </tr> <tr> <td>Trudeau et al<sup>[5]</sup></td> <td>Temozolomide 150 mg/m<sup>2</sup> days 1-7, 15-21, every 28 days</td> <td>Breast cancer</td> <td>19</td> <td>5</td> <td>0</td> <td>NR</td> <td> </td> </tr> <tr> <td>Rivera et al<sup>[6]</sup></td> <td>Escalating doses of capecitabine and temozolomide</td> <td>Breast cancer</td> <td>24</td> <td>24</td> <td>18</td> <td>3 months</td> <td> </td> </tr> <tr> <td>Franciosi et al<sup>[7]</sup></td> <td> <p>Cisplatin 100 mg/m<sup>2</sup> day 1</p> <p>Etoposide 100 mg/m<sup>2</sup> days 1, 3, and 5, every 21 days</p> </td> <td>Solid tumors</td> <td>107</td> <td>56</td> <td>38 (in subset of patients with breast cancer)</td> <td>4 months</td> <td>No prior radiation therapy allowed; 36 percent of patients had not had prior systemic treatment for breast cancer</td> </tr> <tr> <td>Christodoulou et al<sup>[8]</sup></td> <td> <p>Temozolomide 150 mg/m<sup>2</sup> days 1-5</p> <p>Cisplatin 75 mg/m<sup>2</sup> day 1, every 21 days</p> </td> <td>Solid tumors</td> <td>32</td> <td>15</td> <td>40 (in subset of patients with breast cancer)</td> <td>2.9 months</td> <td> </td> </tr> <tr> <td>Lin et al<sup>[9]</sup></td> <td>Lapatinib</td> <td>HER2+ breast cancer</td> <td>39</td> <td>39</td> <td>2.6</td> <td>3 months</td> <td>64 percent had two or more prior lines of systemic treatment (trastuzumab plus chemotherapy) </td> </tr> <tr> <td>Lin et al<sup>[10]</sup></td> <td>Lapatinib</td> <td>HER2+ breast cancer</td> <td>237</td> <td>237</td> <td>6</td> <td>2.4 months</td> <td>All patiens previously treated with radiation therapy; overall survival was 6 months</td> </tr> </tbody></table>
<!--[if gte mso 9]><xml>
<mso:CustomDocumentProperties>
<mso:Specialty msdt:dt="string">11</mso:Specialty>
<mso:Edit_Table msdt:dt="string">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48497&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>
</mso:CustomDocumentProperties>
</xml><![endif]-->
</div><div class="graphic_footnotes">TTP: time to tumor progression; PFS: progress-free survival; NR: not reported; CFP: cyclophosphamide, fluorouracil, and prednisone; CFPMV: cyclophosphamide, fluorouracil, and prednisone plus methotrexate and vincristine; MVP: methotrexate, vincristine, and prednisone; CA: cyclophosphamide and adriamycin; CMF: cyclophosphamide, methotrexate, and fluorouracil; CAF: cyclophosphamide, doxorubicin, and fluorouracil; HER2+: human epidermal growth factor receptor 2.</div><div class="graphic_reference">1. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58:832.<br/> 2. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69:972.<br/> 3. Friedman HS, Evans, B and Reardon, DA. Phase II trial of temozolomide for patients with progressive brain metastases (abstract #408). Proc Am Soc Clin Oncol 2003; 22:102.<br/> 4. Siena S, Landonio G, Beaietta E. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer (abstract #407). Proc Am Soc Clin Oncol 2003; 22:407.<br/> 5. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17:952.<br/> 6. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107:1348.<br/> 7. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85:1599.<br/> 8. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71:61.<br/> 9. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993.<br/> 10. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452.</div><div id="graphicVersion">Graphic 81191 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
